Researchers are reporting on the use of universal base-edited CAR7 T cells as a potential treatment for T-cell acute lymphoblastic leukemia. The therapy has shown promise in treating the disease, with some reports indicating it can induce remission and enable further treatment, such as stem-cell transplantation. However, the approach may also have limitations and potential drawbacks that are being critically evaluated.